Immunotherapy Archives

News and Trends 6 Apr 2022

Immunocore Approvals Open Door for TCR Cancer Drugs

The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific drug based on a cancer-hunting protein called a T-cell receptor (TCR). These regulatory wins by the UK firm Immunocore pave the way for other treatments deploying TCRs. TCRs have become a hot topic in immuno-oncology. Many companies are developing cancer […]

April 6, 2022 - 3 minutesmins - By Jonathan Smith

norway cytovation cancer immuno oncology

News and Trends 26 Jan 2022

Norwegian Biotech Put on the Map with €18M Oncology Round

The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway’s biggest Series A rounds in life sciences. Historically, Norway’s biotech scene has not seen the kind of venture capital funding characteristic of health and biotech in the UK and US. However, Norwegian biotech is growing and has seen more successes than many […]

January 26, 2022 - 3 minutesmins - By Dan Samorodnitsky

London UK venture capital adendra therapeutics apple tree partners

News and Trends 14 Dec 2021

ATP Blazes US Venture Capital Trail into European Biotech Startups

The US venture capital firm Apple Tree Partners (ATP) is making its first transatlantic foray by launching the UK immuno-oncology company Adrendra Therapeutics. This happens as US investors increasingly search for value-for-money opportunities in early-stage European biotech startups. Last week, the life science-focused investor ATP contributed €47M (£40M) to the Series A launch of immunotherapy […]

December 14, 2021 - 4 minutesmins - By Anita Chakraverty

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […]

July 28, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 26 Jul 2021

Europe’s TCR Therapy Scene Gains Traction with €40M Series B

Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies developing cell therapies for cancer based on engineering T-cell receptors (TCRs), known as TCR or TCR-T cell therapies. […]

July 26, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 8 Jul 2021

The Top European Biotech Funding Rounds in June

While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […]

July 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

dna sequencing covid 19 vaccine funding european biotech investment

News and Trends 10 Jun 2021

The Top European Biotech Investment Rounds in May

Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […]

June 10, 2021 - 4 minutesmins - By Jonathan Smith

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […]

May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Immunocore Approvals Open Door for TCR Cancer Drugs

Norwegian Biotech Put on the Map with €18M Oncology Round

ATP Blazes US Venture Capital Trail into European Biotech Startups

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

Microbiome Medicines Could Power Up CAR-T Cell Therapies

Europe’s TCR Therapy Scene Gains Traction with €40M Series B

The Top European Biotech Funding Rounds in June

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

The Top European Biotech Investment Rounds in May

Immuno-Oncology: From Science Fiction to the Mainstream

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!